US Pharm. 2011;36(1):60.
Sagent Pharmaceuticals, Inc., announced the FDA's approval of four presentations of midazolam injection, USP, a general anesthetic. Sagent plans on launching midazolam, which will be offered in latex-free vials, in 2011. According to 2010 IMS Health data, the annual U.S. market for injectable midazolam approximated $52 million. Midazolam is indicated for preoperative use (sedation, anxiolysis, amnesia) prior to or during diagnostic, therapeutic, or endoscopic procedures; intravenously for induction of general anesthesia; and for continuous intravenous infusion for sedation of intubated and mechanically ventilated patients.
“Approval of midazolam marks the ninth FDA approval from our collaboration with Strides Arcolab and is an important addition to our anesthesiology portfolio,” said Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent. “Each of our anesthesiology products, as well as all of our injectable products, includes Sagent's proprietary PreventIV Measures packaging and labeling designed to help with the reduction of medication errors.”
